DAX ®13.054,80-0,65%TecDAX ®3.037,12-0,16%Dow Jones27.677,79+0,10%NASDAQ 1008.308,40+0,14%

PRESS RELEASE: Eckert & Ziegler: Strong nine-month figures. Annual forecast confirmed. Pooling of medical segments in 2020.

| Quelle: Dow Jones Newsw... | Lesedauer etwa 4 min. | Text vorlesen Stop Pause Fortsetzen

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): 9
Month figures
Eckert & Ziegler: Strong nine-month figures. Annual forecast confirmed.
Pooling of medical segments in 2020.

2019-11-12 / 08:50
The issuer is solely responsible for the content of this announcement.

Berlin, 12 November 2019.Berlin-based Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700, S-DAX), a specialist in isotope-related
applications in medicine, science and industry, achieved earnings after tax of
EUR 5.7 million or 1.11 EUR per share in the third quarter 2019. Compared to
the previous year, earnings after tax for the first nine months increased by
46% from EUR 2.50 to EUR 3.66 per share. During the same period, sales
increased by 8% from EUR 123.8 million to EUR 133.2 million. The main driver
of growth was the Radiopharma segment, while the Isotope Products and
Radiation Therapy segments essentially came in at the same level as the
comparable period in the previous year. Along with top line growth, the higher
net profit for the year was also attributable to a more favorable product mix.

With sales revenue of EUR 84.1 million, the Isotope Products segment continues
to be the largest segment. Because the product mix was more favorable compared
with the previous year, the gross margin rose by EUR 2.6 million despite a
comparatively small rise in sales. The segment achieved an overall result of
EUR 8.5 million and thus came in at about the level of the comparable period
in the previous year.

The Radiopharma segment posted a year-on-year increase in sales revenue of EUR
9.1 million. At the same time, manufacturing costs rose at a
disproportionately low level by EUR 1.4 million, resulting in a gross margin
that was on whole higher by EUR 7.7 million than that in the previous year.
The result for this segment therefore rose by a total of EUR 5.0 million, or
91%, compared with the first nine months of 2018.

The Radiation Therapy segment recorded a profit of EUR 0.6 million for the
period, which was nearly unchanged compared with the previous year. With sales
declining by EUR 0.6 million, the gross margin fell somewhat
disproportionately by EUR 0.7 million.

*Confirmation of forecast for 2019*
Despite the strong figures of the first nine months, the Executive Board
confirms its forecast for 2019 of about EUR 4.00, per share. This forecast
takes into account the impairment test estimation results, which are regularly
performed in the fourth quarter, and thus any foreseen one-time adjustment of
specific milestone payments which may occur. In addition, the company is
expecting to receive a fine from the German Federal Financial Supervisory
Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) due to formal
mistakes in the mid-year reports for 2017 and 2018 (missing balance sheet
oath). Although they are difficult to estimate, the one-time special charges
may not exceed EUR 1.8 million. The sales estimation for the financial year
2019 remains of about EUR 180 million.

*Pooling of medical segments*
Starting January 1, 2020, Eckert & Ziegler will consolidate its Radiation
Therapy and Radiopharma segments under the new name "Medical". The pooling of
these two segments is intended to make better use of synergies and achieve
increased efficiency. Dr. Harald Hasselmann, Executive Board member and
currently responsible for the Radiation Therapy segment, will be in charge of
sales within the new Medical segment starting January 1, 2020. Dr. Lutz
Helmke, Executive Board member and currently responsible for the Radiopharma
segment, will assume overall responsibility for operational issues. The
Isotope Products segment remains unchanged.

The complete financial statements can be viewed here:
tsch/euz319e.pdf [1]

*About Eckert & Ziegler. *
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with around
800 employees, is one of the world's largest providers of isotope-related
components for radiation therapy and nuclear medicine. Eckert & Ziegler shares
(ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
*Contributing to saving lives.*

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com [2]

2019-11-12 Dissemination of a Corporate News, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
13125 Berlin
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
EQS News ID: 910373

End of News DGAP News Service

910373 2019-11-12

1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=f53b7364bff98ececad15ce69928b09c&application_id=910373&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=f8525ca55295fb1907527afac25224be&application_id=910373&site_id=vwd&application_name=news

(END) Dow Jones Newswires

November 12, 2019 02:50 ET ( 07:50 GMT)

Das könnte Sie auch interessieren



Aktuelle Videos

zur Mediathek

Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Was wünschen Sie sich von der Großen Koalition?
Jetzt abstimmen!
Alle Umfragen ansehen